XNAS
BKYI
Market cap2mUSD
Oct 08, Last price
1.74USD
1D
-1.14%
1Q
-65.06%
Jan 2017
-99.95%
Name
BIO-Key International Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions in the United States and internationally. It offers BIO-key PortalGuard and PortalGuard IDaaS cloud-based identity platforms, which allows authentication through an IAM platform; and BIO-key VST and WEB-key; civil and large-scale ID infrastructure. The company also provides fingerprint readers for commercial companies under the SidePass, SideSwipe, and EcoID II brands; and identity and access management, user multi-factor authentication, single sign on, privilege entitlement, and access control. It serves commercial, government, and education customers. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Holmdel, New Jersey.
Key people
Michael Depasquale
Chairman of the Board, Chief Executive Officer · since 2014
Kwok Fong Wong
Vice Chairman of the Board · since 2019
Cecilia Welch
Chief Financial Officer · since 2009
James Sullivan
Senior Vice President - Strategy and Compliance, Chief Legal Officer · since 2020
Mira LaCous
Chief Technology Officer · since 2014
Emmanuel Alia
Independent Director · since 2020
Independent Director · since 2017
Cameron Williams
Independent Director · since 2023
Legal address
C/O Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
251 Little Falls Drive
Wilmington, DE 19808
US
Headquarters
3349 Highway 138
Building A
Suite E
Wall, NJ 07719
US
Building A
Suite E
Wall, NJ 07719
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||